Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 5
2001 6
2002 11
2003 22
2004 21
2005 30
2006 26
2007 31
2008 58
2009 48
2010 65
2011 49
2012 81
2013 94
2014 105
2015 101
2016 97
2017 116
2018 128
2019 62
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

1,022 results
Results by year
Filters applied: . Clear all
Page 1
Pancreatic cancer.
Kamisawa T, et al. Lancet 2016 - Review. PMID 26830752
There is no standard programme for screening patients at high risk of pancreatic cancer (eg, those with a family history of pancreatic cancer and chronic pancreatitis). Most pancreatic cancers arise from microscopic non-invasive epithelial proliferations within the pancreatic ducts, referred to as pancreatic intraepithelial neoplasias. ...
There is no standard programme for screening patients at high risk of pancreatic cancer (eg, those with a family history of pancre
Early Detection of Pancreatic Cancer: Opportunities and Challenges.
Singhi AD, et al. Gastroenterology 2019 - Review. PMID 30721664 Free PMC article.
Most patients with pancreatic ductal adenocarcinoma (PDAC) present with symptomatic, surgically unresectable disease. Although the goal of early detection of PDAC is laudable and likely to result in significant improvement in overall survival, the relatively low prevalence of PDAC renders general population screening infeasible. ...In recent years, various subgroups at higher-than-average risk for PDAC have been identified, including those with familial risk due to germline mutations, a history of pancreatitis, patients with mucinous pancreatic cysts, and elderly patients with new-onset diabetes. ...
Most patients with pancreatic ductal adenocarcinoma (PDAC) present with symptomatic, surgically unresectable disease. Although …
Diagnosis and staging of pancreatic ductal adenocarcinoma.
Guillén-Ponce C, et al. Clin Transl Oncol 2017 - Review. PMID 28612200
The management of pancreatic ductal adenocarcinoma (PDAC) is a major public health concern worldwide. Currently, most PDAC patients are diagnosed in advanced stages. ...In this article, the group of experts proposes strategies to shorten the diagnosis times in PDAC patients....
The management of pancreatic ductal adenocarcinoma (PDAC) is a major public health concern worldwide. Currently, most PDAC pat …
Imaging diagnosis of pancreatic cancer: a state-of-the-art review.
Lee ES and Lee JM. World J Gastroenterol 2014 - Review. PMID 24976723 Free PMC article.
Due to the lack of early symptoms and the tendency of pancreatic adenocarcinoma to invade adjacent structures or to metastasize at an early stage, many patients with pancreatic cancer already have advanced disease at the time of their diagnosis and, therefore, there is a high mortality rate. ...The diagnosis could be improved using positron emission tomography techniques in special conditions in which CT and EUS are not completely diagnostic. ...
Due to the lack of early symptoms and the tendency of pancreatic adenocarcinoma to invade adjacent structures or to metastasize at an …
Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
Mayerle J, et al. Gut 2018 - Clinical Trial. PMID 28108468 Free PMC article.
OBJECTIVE: Current non-invasive diagnostic tests can distinguish between pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC)) and chronic pancreatitis (CP) in only about two thirds of patients. ...RESULTS: A biomarker signature (nine metabolites and additionally CA19-9) was identified for the differential diagnosis between PDAC and CP. ...
OBJECTIVE: Current non-invasive diagnostic tests can distinguish between pancreatic cancer (pancreatic ductal adenocarc …
Imaging mimics of pancreatic ductal adenocarcinoma.
Gandhi NS, et al. Abdom Radiol (NY) 2018 - Review. PMID 29038855
Pancreatic ductal adenocarcinoma is the most common primary malignancy of the pancreas. The classic imaging features are a hypovascular mass with proximal ductal dilatation. Different pancreatic pathologies can mimic the imaging appearance of carcinoma including other tumors involving the pancreas (pancreatic neuroendocrine tumors, lymphoma, metastasis, and rare tumors like pancreatic acinar cell carcinoma and solid pseudopapillary tumors), inflammatory processes (chronic pancreatitis and autoimmune pancreatitis), and anatomic variants (annular pancreas). ...
Pancreatic ductal adenocarcinoma is the most common primary malignancy of the pancreas. The classic imaging features are a hyp
Possible Molecular Markers for the Diagnosis of Pancreatic Ductal Adenocarcinoma.
Shen Q, et al. Med Sci Monit 2018. PMID 29671412 Free PMC article.
BACKGROUND We aimed to identify pivotal genes and pathways involved in pancreatic ductal adenocarcinoma (PDAC), and explore possible molecular markers for the early diagnosis of the disease. ...In addition, ribosomal protein genes Nup170, Nup160, and HNRNPU may be used as possible molecular markers for the early diagnosis of the disease....
BACKGROUND We aimed to identify pivotal genes and pathways involved in pancreatic ductal adenocarcinoma (PDAC), and explore po …
Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection.
Becker AE, et al. World J Gastroenterol 2014 - Review. PMID 25170203 Free PMC article.
Pancreatic cancer is the fourth most common cause of cancer-related deaths in the United States, with over 38000 deaths in 2013. The opportunity to detect pancreatic cancer while it is still curable is dependent on our ability to identify and screen high-risk populations before their symptoms arise. ...
Pancreatic cancer is the fourth most common cause of cancer-related deaths in the United States, with over 38000 deaths in 2013. The
Efficacy and safety of pancreatic juice cytology by using synthetic secretin in the diagnosis of pancreatic ductal adenocarcinoma.
Takeda Y, et al. Dig Endosc 2018. PMID 29873113
BACKGROUND AND AIM: Pancreatic ductal adenocarcinoma (PDAC) is difficult to detect in its early stages with the poorest prognosis of all cancers. ...Pancreatic juice cytology (PJC), the sensitivity of which is 33.3-65.8%, is a method for the diagnosis of PDAC cases in which carrying out of EUS-FNA is difficult. ...
BACKGROUND AND AIM: Pancreatic ductal adenocarcinoma (PDAC) is difficult to detect in its early stages with the poorest progno …
Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance.
Canto MI, et al. Gastroenterology 2018. PMID 29803839 Free PMC article.
BACKGROUND & AIMS: Screening of individuals who have a high risk of pancreatic ductal adenocarcinoma (PDAC), because of genetic factors, frequently leads to identification of pancreatic lesions. ...Neoplastic progression occurred at a median age of 67 years; the median time from baseline screening until PDAC diagnosis was 4.8 years (interquartile range, 1.6-6.9 years). ...
BACKGROUND & AIMS: Screening of individuals who have a high risk of pancreatic ductal adenocarcinoma (PDAC), because of ge …
1,022 results
Jump to page
Feedback